DK1638969T3 - CGRP-receptorantagonister - Google Patents

CGRP-receptorantagonister

Info

Publication number: DK1638969T3
Authority: DK; Denmark
Prior art keywords: receptor antagonists; cgrp receptor; cgrp; antagonists; receptor
Prior art date: 2003-04-15

Application number

DK04749887T

Other languages

English (en)

Inventor

Christopher S Burgey

Zhengwu J Deng

Diem N Nguyen

Daniel V Paone

Anthony W Shaw

Theresa M Williams

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-15

Filing date

2004-04-09

Publication date

2009-01-26

2004-04-09 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2009-01-26 Application granted granted Critical

2009-01-26 Publication of DK1638969T3 publication Critical patent/DK1638969T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Addiction (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Oncology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK04749887T 2003-04-15 2004-04-09 CGRP-receptorantagonister DK1638969T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46308903P	2003-04-15	2003-04-15
US51035203P	2003-10-10	2003-10-10
PCT/US2004/010851 WO2004092166A2 (en)	2003-04-15	2004-04-09	Cgrp receptor antagonists

Publications (1)

Publication Number	Publication Date
DK1638969T3 true DK1638969T3 (da)	2009-01-26

Family

ID=33303112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04749887T DK1638969T3 (da)	2003-04-15	2004-04-09	CGRP-receptorantagonister

Country Status (32)

Country	Link
US (6)	US6953790B2 (da)
EP (2)	EP2039694B1 (da)
JP (1)	JP3967766B2 (da)
KR (1)	KR100769030B1 (da)
CN (1)	CN100384843C (da)
AR (1)	AR045887A1 (da)
AT (1)	ATE413400T1 (da)
AU (1)	AU2004230926B2 (da)
BR (1)	BRPI0409601A (da)
CA (1)	CA2522220C (da)
CL (1)	CL2004000788A1 (da)
CO (1)	CO5640130A2 (da)
CY (1)	CY1108714T1 (da)
DE (1)	DE602004017608D1 (da)
DK (1)	DK1638969T3 (da)
EC (1)	ECSP056097A (da)
ES (1)	ES2314417T3 (da)
HR (1)	HRP20080666T3 (da)
IS (1)	IS2759B (da)
JO (1)	JO2355B1 (da)
MA (1)	MA27728A1 (da)
MX (1)	MXPA05011166A (da)
NO (1)	NO327655B1 (da)
NZ (1)	NZ543357A (da)
PE (1)	PE20050020A1 (da)
PL (1)	PL1638969T3 (da)
PT (1)	PT1638969E (da)
RU (1)	RU2308458C2 (da)
SI (1)	SI1638969T1 (da)
TW (1)	TWI314931B (da)
UA (1)	UA82877C2 (da)
WO (2)	WO2004092166A2 (da)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7220862B2 (en)	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
US7842808B2 (en)	2002-06-05	2010-11-30	Bristol-Myers Squibb Company	Anti-migraine spirocycles
GEP20074231B (en) *	2002-06-05	2007-11-12	Bristol Myers Squibb Co	Calcitonin gene related peptide receptor antagonists
CA2522024A1 (en) *	2003-04-15	2004-10-28	Merck & Co., Inc.	Cgrp receptor antagonists
GB0310881D0 (en) *	2003-05-12	2003-06-18	Merck Sharp & Dohme	Pharmaceutical formulation
WO2005000807A2 (en) *	2003-06-26	2005-01-06	Merck & Co., Inc.	Benzodiazepine cgrp receptor antagonists
DE602004026053D1 (da) *	2003-06-26	2010-04-29	Merck Sharp & Dohme
US7569578B2 (en)	2003-12-05	2009-08-04	Bristol-Meyers Squibb Company	Heterocyclic anti-migraine agents
CN101124217A (zh) *	2004-01-29	2008-02-13	默克公司	Cgrp受体拮抗剂
EP1732885A1 (en) *	2004-02-23	2006-12-20	Trustees Of Tufts College	Lactams as conformationally constrained peptidomimetic inhibitors
TW200533398A (en)	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
US7659264B2 (en) *	2004-10-07	2010-02-09	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
CA2583534A1 (en) *	2004-10-14	2006-04-27	Merck & Co., Inc.	Cgrp receptor antagonists
ATE503755T1 (de) *	2004-10-22	2011-04-15	Merck Sharp & Dohme	Cgrp-rezeptorantagonisten
US7384930B2 (en) *	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en)	2004-12-03	2008-11-11	Bristol-Myers Squibb Company	Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) *	2005-02-11	2011-11-09	Cambridge Entpr Ltd	Ligands for G-protein coupled receptors
GB2467060B (en) *	2005-02-11	2010-09-01	Cambridge Entpr Ltd	Ligands for G-protein coupled receptors
US7994325B2 (en)	2005-03-14	2011-08-09	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
US7834007B2 (en)	2005-08-25	2010-11-16	Bristol-Myers Squibb Company	CGRP antagonists
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
WO2007054809A2 (en)	2005-11-14	2007-05-18	Rinat Neuroscience Corp.	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN100371327C (zh) *	2005-11-17	2008-02-27	江苏工业学院	2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
AU2006316627A1 (en) *	2005-11-18	2007-05-31	Merck Sharp & Dohme Corp.	Spirolactam aryl CGRP receptor antagonists
DE602007002182D1 (de)	2006-04-10	2009-10-08	Merck & Co Inc	Verfahren zur herstellung von cgrp-antagonisten
AU2007238894A1 (en) *	2006-04-10	2007-10-25	Merck Sharp & Dohme Corp.	Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
ES2328186T3 (es) *	2006-04-10	2009-11-10	MERCK & CO., INC.	Procedimiento de preparacion de un intermedio de antagonista del cgrp de caprolactama.
AU2007238896A1 (en) *	2006-04-10	2007-10-25	Merck Sharp & Dohme Corp.	CGRP antagonist salt
WO2007130927A2 (en) *	2006-05-02	2007-11-15	Bristol-Myers Squibb Company	Condensed tricyclic compounds as cgrp-receptor antagonists
US7470680B2 (en) *	2006-05-03	2008-12-30	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
CA2650932C (en) *	2006-05-09	2013-01-22	Merck & Co., Inc.	Substituted spirocyclic cgrp receptor antagonists
ZA200810791B (en) *	2006-06-13	2010-03-31	Vertex Pharma	CGRP receptor antagonists
US8163737B2 (en)	2006-06-13	2012-04-24	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
US7834000B2 (en)	2006-06-13	2010-11-16	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
US8227603B2 (en)	2006-08-01	2012-07-24	Cytokinetics, Inc.	Modulating skeletal muscle
AU2007281468B2 (en) *	2006-08-02	2012-12-06	Cytokinetics, Incorporated	Certain chemical entities, compositions and methods
US8299248B2 (en)	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101511184A (zh) *	2006-09-08	2009-08-19	默克公司	用于口服给药cgrp拮抗剂的液体药物制剂
EP2152690B1 (en)	2007-05-23	2012-01-11	Merck Sharp & Dohme Corp.	Pyridyl piperidine orexin receptor antagonists
GB0712392D0 (en) *	2007-06-26	2007-08-01	Glaxo Group Ltd	Novel compounds
US20090075977A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched mk0974
CA2722536A1 (en) *	2008-02-05	2009-08-13	Merck & Co., Inc.	Prodrugs of cgrp receptor antagonist
US8796260B2 (en)	2008-02-19	2014-08-05	Merck Sharp & Dohme Corp.	Imidazobenzazepine CGRP receptor antagonists
EP2265287B1 (en)	2008-03-04	2018-09-05	Teva Pharmaceuticals International GmbH	Methods of treating chronic pain
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8143403B2 (en)	2008-04-11	2012-03-27	Bristol-Myers Squibb Company	CGRP receptor antagonists
RU2011103170A (ru) *	2008-06-30	2012-08-10	Мерк Шарп Энд Домэ Корп. (Us)	Твердые дозированные составы телкагепанта калия
EP2348846B1 (en)	2008-10-21	2013-08-28	Merck Sharp & Dohme Corp.	Disubstituted azepan orexin receptor antagonists
US8715715B2 (en)	2008-11-03	2014-05-06	Nal Pharmaceuticals Ltd.	Dosage form for insertion into the mouth
MX2012002464A (es)	2009-08-28	2012-03-14	Rinat Neuroscience Corp	El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
US8314117B2 (en)	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8669368B2 (en)	2010-10-12	2014-03-11	Bristol-Myers Squibb Company	Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI487706B (zh)	2010-11-12	2015-06-11	Merck Sharp & Dohme	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012129014A1 (en) *	2011-03-18	2012-09-27	Merck Sharp & Dohme Corp.	Piperidine carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en)	2011-04-12	2014-06-10	Bristol-Myers Squibb Company	CGRP receptor antagonists
RS66303B1 (sr)	2011-05-20	2025-01-31	H Lundbeck As	Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
EP3662932B1 (en)	2011-05-20	2021-04-07	H. Lundbeck A/S	Anti-cgrp compositions and use thereof
EA033109B1 (ru)	2011-05-20	2019-08-30	Олдербайо Холдингз Ллк	Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
CN109316480A (zh)	2011-07-13	2019-02-12	赛特凯恩蒂克公司	组合als疗法
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
LT2820016T (lt)	2012-02-27	2017-10-25	Bristol-Myers Squibb Company	N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska
CN104203925A (zh)	2012-03-29	2014-12-10	拜耳知识产权有限责任公司	5-氨基嘧啶衍生物及其用于防治不希望的植物生长的用途
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
KR20220136460A (ko)	2014-02-05	2022-10-07	머크 샤프 앤드 돔 엘엘씨	Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en)	2014-02-05	2024-12-17	Merck Sharp & Dohme Llc	Treatment of migraine
BR112016021423A2 (pt)	2014-03-21	2017-11-14	Teva Pharmaceuticals Int Gmbh	anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201417707D0 (en)	2014-10-07	2014-11-19	Viral Ltd	Pharmaceutical compounds
WO2017001434A1 (en) *	2015-06-29	2017-01-05	Galderma Research & Development	Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
KR20220031944A (ko)	2016-09-23	2022-03-14	테바 파마슈티컬스 인터내셔널 게엠베하	불응성 편두통의 치료
EP3366286A1 (en)	2017-02-22	2018-08-29	Johannes Keller	Compounds for treating sepsis
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
JP7281470B2 (ja)	2018-01-19	2023-05-25	イドーシアファーマシューティカルズリミテッド	Ｃ５ａ受容体調節剤
US12383545B1 (en)	2018-06-08	2025-08-12	Allergan Pharmaceuticals International Limited	Treatment of migraine
US12090148B2 (en)	2020-07-29	2024-09-17	Allergan Pharmaceuticals International Limited	Treatment of migraine
CN108892635A (zh) *	2018-09-07	2018-11-27	江苏工程职业技术学院	一种西沙必利关键中间体的制备方法
CN113227140A (zh)	2019-01-08	2021-08-06	H.隆德贝克有限公司	使用抗cgrp抗体急性治疗和快速治疗头痛
GB201908430D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
GB201908420D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
BR102020007149A8 (pt)	2020-04-06	2023-09-26	H Lundbeck As	Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
CA3206184A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
EP4301362A1 (en)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
US12350259B2 (en)	2021-09-27	2025-07-08	Allergan Pharmaceuticals International Limited	Methods of treating migraine
CN116903616B (zh) *	2023-07-17	2025-08-01	江西同和药业股份有限公司	一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) *	1995-02-01	1996-08-08	Bayer Ag	Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (en)	1995-05-08	1996-11-14	Pfizer, Inc.	Dipeptides which promote release of growth hormone
JP2002525371A (ja) *	1998-09-30	2002-08-13	メルクシャープエンドドームリミテッド	Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
US6355663B1 (en)	1998-09-30	2002-03-12	Taisho Pharmaceutical Co., Ltd.	Substituted isoxazolylthiophene compounds
GEP20074231B (en) *	2002-06-05	2007-11-12	Bristol Myers Squibb Co	Calcitonin gene related peptide receptor antagonists
CA2522024A1 (en) *	2003-04-15	2004-10-28	Merck & Co., Inc.	Cgrp receptor antagonists

2004
- 2004-04-07 JO JO200445A patent/JO2355B1/en active
- 2004-04-09 WO PCT/US2004/010851 patent/WO2004092166A2/en not_active Ceased
- 2004-04-09 PL PL04749887T patent/PL1638969T3/pl unknown
- 2004-04-09 CN CNB2004800161154A patent/CN100384843C/zh not_active Expired - Fee Related
- 2004-04-09 DK DK04749887T patent/DK1638969T3/da active
- 2004-04-09 JP JP2006509818A patent/JP3967766B2/ja not_active Expired - Fee Related
- 2004-04-09 PT PT04749887T patent/PT1638969E/pt unknown
- 2004-04-09 BR BRPI0409601-0A patent/BRPI0409601A/pt not_active IP Right Cessation
- 2004-04-09 AU AU2004230926A patent/AU2004230926B2/en not_active Ceased
- 2004-04-09 ES ES04749887T patent/ES2314417T3/es not_active Expired - Lifetime
- 2004-04-09 CA CA002522220A patent/CA2522220C/en not_active Expired - Fee Related
- 2004-04-09 EP EP08105721.8A patent/EP2039694B1/en not_active Expired - Lifetime
- 2004-04-09 DE DE602004017608T patent/DE602004017608D1/de not_active Expired - Lifetime
- 2004-04-09 SI SI200430961T patent/SI1638969T1/sl unknown
- 2004-04-09 NZ NZ543357A patent/NZ543357A/en not_active IP Right Cessation
- 2004-04-09 RU RU2005135440/04A patent/RU2308458C2/ru not_active IP Right Cessation
- 2004-04-09 WO PCT/US2004/011280 patent/WO2004092168A1/en not_active Ceased
- 2004-04-09 KR KR1020057019692A patent/KR100769030B1/ko not_active Expired - Fee Related
- 2004-04-09 AT AT04749887T patent/ATE413400T1/de active
- 2004-04-09 HR HR20080666T patent/HRP20080666T3/xx unknown
- 2004-04-09 EP EP04749887A patent/EP1638969B1/en not_active Expired - Lifetime
- 2004-04-09 MX MXPA05011166A patent/MXPA05011166A/es active IP Right Grant
- 2004-04-12 PE PE2004000364A patent/PE20050020A1/es not_active Application Discontinuation
- 2004-04-13 CL CL200400788A patent/CL2004000788A1/es unknown
- 2004-04-13 AR ARP040101238A patent/AR045887A1/es active IP Right Grant
- 2004-04-14 TW TW093110393A patent/TWI314931B/zh not_active IP Right Cessation
- 2004-05-04 US US10/838,835 patent/US6953790B2/en not_active Expired - Lifetime
- 2004-09-04 UA UAA200510685A patent/UA82877C2/uk unknown
2005
- 2005-06-14 US US11/152,537 patent/US7235545B2/en not_active Expired - Lifetime
- 2005-09-29 IS IS8055A patent/IS2759B/is unknown
- 2005-10-11 MA MA28550A patent/MA27728A1/fr unknown
- 2005-10-12 CO CO05104372A patent/CO5640130A2/es active IP Right Grant
- 2005-10-12 EC EC2005006097A patent/ECSP056097A/es unknown
- 2005-11-14 NO NO20055375A patent/NO327655B1/no not_active IP Right Cessation
2007
- 2007-03-14 US US11/724,066 patent/US7452903B2/en not_active Expired - Lifetime
2008
- 2008-04-09 US US12/082,233 patent/US7534784B2/en not_active Expired - Lifetime
2009
- 2009-01-15 CY CY20091100053T patent/CY1108714T1/el unknown
- 2009-04-03 US US12/417,911 patent/US7772224B2/en not_active Expired - Lifetime
2010
- 2010-07-07 US US12/831,802 patent/US7893052B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2314417T3 (es)	2009-03-16
IS2759B (is)	2011-10-15
JP3967766B2 (ja)	2007-08-29
RU2005135440A (ru)	2006-03-20
US7534784B2 (en)	2009-05-19
AU2004230926B2 (en)	2008-07-17
AR045887A1 (es)	2005-11-16
CL2004000788A1 (es)	2005-02-25
CY1108714T1 (el)	2014-04-09
TW200505903A (en)	2005-02-16
EP1638969A2 (en)	2006-03-29
MA27728A1 (fr)	2006-01-02
US20080280857A1 (en)	2008-11-13
CN100384843C (zh)	2008-04-30
IS8055A (is)	2005-09-29
US20050256098A1 (en)	2005-11-17
MXPA05011166A (es)	2005-12-14
US7772224B2 (en)	2010-08-10
NZ543357A (en)	2008-08-29
CO5640130A2 (es)	2006-05-31
EP1638969B1 (en)	2008-11-05
PL1638969T3 (pl)	2009-04-30
US20040229861A1 (en)	2004-11-18
SI1638969T1 (sl)	2009-02-28
EP2039694A1 (en)	2009-03-25
US7452903B2 (en)	2008-11-18
US6953790B2 (en)	2005-10-11
CN1802376A (zh)	2006-07-12
RU2308458C2 (ru)	2007-10-20
WO2004092168A1 (en)	2004-10-28
JO2355B1 (en)	2006-12-12
AU2004230926A1 (en)	2004-10-28
PE20050020A1 (es)	2005-02-18
US20100298303A1 (en)	2010-11-25
KR100769030B1 (ko)	2007-10-22
CA2522220A1 (en)	2004-10-28
NO20055375L (no)	2005-11-14
DE602004017608D1 (de)	2008-12-18
PT1638969E (pt)	2009-01-16
CA2522220C (en)	2009-06-23
US20090192139A1 (en)	2009-07-30
WO2004092166A3 (en)	2005-01-20
JP2006523697A (ja)	2006-10-19
UA82877C2 (en)	2008-05-26
WO2004092166A2 (en)	2004-10-28
US20070225272A1 (en)	2007-09-27
US7235545B2 (en)	2007-06-26
HRP20080666T3 (en)	2009-01-31
HK1090922A1 (en)	2007-01-05
TWI314931B (en)	2009-09-21
NO327655B1 (no)	2009-09-07
US7893052B2 (en)	2011-02-22
BRPI0409601A (pt)	2006-04-18
KR20050121734A (ko)	2005-12-27
ATE413400T1 (de)	2008-11-15
EP2039694B1 (en)	2014-03-26
ECSP056097A (es)	2006-03-01

Publication	Publication Date	Title
DK1638969T3 (da)	2009-01-26	CGRP-receptorantagonister
DK1682142T3 (da)	2012-10-15	M3-muscarin-acetylcholin-receptor-antagonister
DK1951660T3 (da)	2014-01-27	Histamin-3-receptorantagonister
ATE494285T1 (de)	2011-01-15	Muscarinische acetylcholin-rezeptor-antagonisten
NO20051871D0 (no)	2005-04-18	Opioid reseptorantagonister
CY2015029I2 (el)	2016-04-13	Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
ATE452886T1 (de)	2010-01-15	Chemokinrezeptorantagonisten
PT2570128T (pt)	2016-10-07	Antagonistas do receptor muscarínico de acetilcolina
EP1641781A4 (en)	2010-06-23	BENZODIAZEPINE-CGRP Receptor Antagonists
EP1765805A4 (en)	2009-08-26	CGRP RECEPTOR ANTAGONISTS
DK1711465T3 (da)	2008-03-31	Hydroisoindolin-tachykinikreceptorantagonister
DE60216229D1 (de)	2007-01-04	Il-8-rezeptorantagonisten
DK1973886T3 (da)	2013-03-18	Prokineticin-1-receptor-antagonister
DE60316411D1 (de)	2007-10-31	Thiazolderivate als npy-rezeptorantagonisten
EP1799672A4 (en)	2011-01-19	CGRP RECEPTOR ANTAGONIST
FI20060188L (fi)	2006-02-24	Modifioidut IL-4-muteiinin reseptorin antagonistit
NO20033223D0 (no)	2003-07-16	Histamin-reseptor antagonister
ATE528291T1 (de)	2011-10-15	Cyclopropylderivate als nk3 rezeptor-antagonisten
DE60209885D1 (de)	2006-05-11	Crf receptor antagonisten
EP1534736A4 (en)	2006-11-02	ANTAGONISTS OF NOGO RECEPTOR
DE602004018527D1 (de)	2009-01-29	Furanderivate als ep4-rezeptorantagonisten
DE602005007719D1 (de)	2008-08-07	Antagonisten des opioidrezeptors